* Amedisys Inc AMED.OQ AMED.O is expected to show a rise
in
quarterly revenue when it reports results on May 3.
* The Baton Rouge Louisiana-based company is expected to
report
a 2.5% increase in revenue to $558.692 million from $545.26
million a year ago, according to the mean estimate from 16
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Amedisys Inc is for
earnings of 89 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 7
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months.
* Wall Street's median 12-month price target for Amedisys
Inc is
$107, above its last closing price of $75.71.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 0.97 1.00 1.16 Beat 15.5
Sep. 30 2022 1.21 1.22 1.15 Missed -5.5
Jun. 30 2022 1.23 1.23 1.47 Beat 19.5
Mar. 31 2022 1.12 1.12 1.23 Beat 9.4
Dec. 1.19 1.18 1.18 Met 0.3
31 2021
Sep. 30 2021 1.37 1.37 1.53 Beat 11.9
Jun. 30 2021 1.69 1.66 1.69 Beat 1.5
Mar. 31 2021 1.43 1.43 1.54 Beat 7.9
This summary was machine generated April 21 at 12:39 GMT. All
figures in US dollars unless otherwise stated